Skip to main content
Premium Trial:

Request an Annual Quote

NCI's CPTAC Enters MOUs with Taiwanese Institutes for Cancer Biomarker Research

NEW YORK(GenomeWeb) – The National Cancer Institute's Clinical Proteomic Tumor Analysis Consortium (CPTAC) said today it has entered into memoranda of understanding with Chang Gung Universityand Academia Sinica in Taipei, Taiwan.

Together, the organizations will cooperate on using proteomic methods to characterize tumors and compare these proteomic characterizations to other forms of data including genomic profiles, CPTAC organizers said in a statement.

According to CPTAC, the aim of the collaboration is to identify targets and pathways of therapeutic intervention, support development of proteogenomic methods, and gain increased understanding of cancer at the molecular level.

Both institutions bring specific areas of expertise to the CPTAC collaboration with Chang Gung University's Molecular Medicine Research Center specializing in cancer biomarker research and development, and Academia Sinica focusing on proteogenomic studies of cancer as part of the Taiwan Biobank Project. 

Financial and other terms of the agreement were not disclosed.